10 Best German Stocks To Buy Now

7. BioNTech SE (NASDAQ:BNTX)

Upside potential as of November 15: 37.93%

The biotechnology company BioNTech SE (NASDAQ:BNTX), headquartered in Germany, is focused on creating vaccinations against infectious diseases like COVID-19 and cancer treatments, such as personalized immunotherapy. BNTX is one of the best German stocks, returning over 7.5% in the past 12 months.

The company’s oncology pipeline includes several pharmacological types, such as cell treatments, bispecific antibodies, antibody-drug conjugates, or ADCs, and mRNA-based medications that encode antigens, neoantigens, cytokines, and antibodies. Several major pharmaceutical companies, such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, are partners of BioNTech. Its first commercially available product is the COVID-19 vaccination, Comirnaty.

In the third quarter of 2024, BioNTech SE (NASDAQ:BNTX) reported revenue of EUR 1.2 billion ($1.27 billion), a 39% increase over the same period the previous year. The increased revenue is attributed to the earlier approvals for BioNTech’s variant-adapted COVID-19 vaccines compared to last year. Moreover, in Q3 2024, research and development expenses were €550.3 million ($582.7 million), compared to €497.9 million ($527.2 million) in the previous year period. R&D expenses were primarily driven by clinical trials for the company’s late-stage cancer pipeline prospects.

During the latest quarter, BioNTech SE (NASDAQ:BNTX) made significant strides in its oncology pipeline and successfully launched our variant-adapted COVID-19 vaccines. Specifically, the company announced major improvements for its mRNA cancer vaccine portfolio and its PD-L1 x VEGF-A bispecific antibody candidate BNT327/PM8002 and started later-stage trials. These achievements support the company’s multi-platform technological approach’s potential and guide the development of innovative proprietary combinations.